The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients.
The periodontal health of 30 adult epileptic patients treated with either sodium valproate or phenytoin was compared with a control group (n = 15) of otherwise healthy patients. The 3 groups were matched for age and sex. Patients on phenytoin therapy showed significantly higher plaque scores (P less than 0.05), gingival index (P less than 0.05) and pocketing (P less than 0.05) than patients in the control group. The % of gingival hyperplasia was significantly higher (P less than 0.05) in the phenytoin-treated patients than those on sodium valproate or in the control group. However, patients on phenytoin therapy had significantly less bone loss than those on sodium valproate (P less than 0.05) or in the control group (P less than 0.01). No significant differences were observed between the sodium valproate group and the control group on any of the parameters assessed. The results from this study would suggest that sodium valproate has no unwanted effects on periodontal health and may be considered a safe alternative, regarding the periodontal aspects, to phenytoin for the treatment of adult onset epilepsy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000539:Alveolar Process / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced; D003430:Cross-Sectional Studies; D003774:Dental Plaque Index; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005885:Gingival Hyperplasia / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009910:Oral Hygiene; D010510:Periodontal Diseases / Q000139:chemically induced*; D010512:Periodontal Index; D010672:Phenytoin / Q000009:adverse effects*; D014635:Valproic Acid / Q000009:adverse effects*
D014635:Valproic Acid; D010672:Phenytoin